EUVIMEDEUVIMED entdecken
Crossref

Use of Infliximab in Infantile Kawasaki Disease: Experiences over 8 Years

C Ravali Pratima Goud iD, Rhea Singh, Anindita Nandi, Jigna N Bathia, Priyankar Pal iD

Indian Pediatrics · 2026

DOI: 10.1007/s13312-025-00221-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Indian Pediatrics, 2026. Verfasst von C Ravali Pratima Goud und 4 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Rheumatology Unit, Institute of Child Health, Dr Biresh Guha Street, Park Circus, Kolkata, India. Hauptthemen laut MEDLINE: Mucocutaneous Lymph Node Syndrome, Infliximab. Die Arbeit nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Data on the use of infliximab (IFX) in infants with Kawasaki disease (KD) are scant. We retrospectively analyzed data of 35 infants with KD who received IFX. Effectiveness of IFX was assessed in the presence of intravenous immunoglobulin (IVIG) resistance and coronary artery aneurysm (CAA) regression. Fifteen of thirty-five received IFX in the presence of IVIG resistance; nineteen of thirty-five for CAA; and one for persistently high c-reactive protein. Thirteen out of fifteen with IVIG resistance became afebrile by 24 h. Twelve medium CAA regressed over 3 months, four of ten giant CAA normalized, and three regressed to small CAA, median time being 7.5 (3.5, 18) months. IFX was well-tolerated, safe, and effective in infants with KD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mucocutaneous Lymph Node SyndromeInfliximabHumansInfantMaleRetrospective StudiesFemaleImmunoglobulins, IntravenousCoronary AneurysmTreatment Outcome

Stichwörter der Autor:innen

Anti-tumor necrosis factor-alphaCoronary artery aneurysmIVIG resistanceRefractory Kawasaki diseaseTNF-α

Substanzen

InfliximabImmunoglobulins, Intravenous

Autor:innen und Institutionen

  • Pediatric Rheumatology Unit, Institute of Child Health, Dr Biresh Guha Street, Park Circus, Kolkata, India.
  • Pediatric Rheumatology Unit, Institute of Child Health, Dr Biresh Guha Street, Park Circus, Kolkata, India. mailme.priyankar@gmail.com.
  • Department of Pediatrics, Institute of Child Health, Kolkata, India. mailme.priyankar@gmail.com.

ORCID-Profile: C Ravali Pratima Goud, Priyankar Pal

Zitieren

APA

Goud, C. R. P., Singh, R., Nandi, A., Bathia, J. N., & Pal, P. (2026). Use of Infliximab in Infantile Kawasaki Disease: Experiences over 8 Years. Indian Pediatrics. https://doi.org/10.1007/s13312-025-00221-3

Vancouver

Goud CRP, Singh R, Nandi A, Bathia JN, Pal P. Use of Infliximab in Infantile Kawasaki Disease: Experiences over 8 Years. Indian Pediatrics. 2026. doi:10.1007/s13312-025-00221-3

BibTeX
@article{Goud2026,
  author = {Goud, C Ravali Pratima and Singh, Rhea and Nandi, Anindita and Bathia, Jigna N and Pal, Priyankar},
  title = {Use of Infliximab in Infantile Kawasaki Disease: Experiences over 8 Years},
  journal = {Indian Pediatrics},
  year = {2026},
  doi = {10.1007/s13312-025-00221-3}
}
Kostenlos starten →